针对TEAD-ious抗药性的靶向研究。
Targeting TEAD-ious resistance.
发表日期：2023 Aug 03
作者：
Connor A Ott, Andrew E Aplin
来源：
PHARMACOLOGY & THERAPEUTICS
摘要：
最近在靶向突变的KRAS上取得的进展受到了抗药性的限制。Hagenbeek等人在《自然癌症》杂志上的最新研究利用一种靶向TEAD转录因子的新型抑制剂GNE-7883来克服对KRAS抑制剂的抗药性。因此，TEAD抑制剂可能最大程度地延长癌症患者中KRAS抑制剂的持久性。版权 © 2023 Elsevier Inc. 保留所有权利。
Recent advances in targeting mutant KRAS are limited by resistance. A recent study in Nature Cancer by Hagenbeek et al. utilizes a novel inhibitor that targets the TEAD transcription factor, GNE-7883, to overcome resistance to KRAS inhibitors. Thus, TEAD inhibitors may maximize the durability of KRAS inhibitors in patients with cancer.Copyright © 2023 Elsevier Inc. All rights reserved.